Lysophosphatidic Acid is Associated with Neuropathic Pain Intensity in Humans: An Exploratory Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Nov 9

PMID 30408112

Citations 24

Authors

Ken Kuwajima

Masahiko Sumitani

Makoto Kurano

Kuniyuki Kano

Masako Nishikawa

Baasanjav Uranbileg

Rikuhei Tsuchida

Toru Ogata

Junken Aoki

Yutaka Yatomi

Yoshitsugu Yamada

Affiliations

Soon will be listed here.

Abstract

The underlying mechanisms of neuropathic pain remain to be elucidated. Basic animal research has suggested that lysophosphatidic acids, which are bioactive lipids produced by autotaxin from lysophosphatidylcholine, may play key roles in the initiation and maintenance of neuropathic pain. Here, we investigated the clinical relevance of lysophosphatidic acids signaling on neuropathic pain in humans. Eighteen patients who had been diagnosed with neuropathic pain with varied etiologies participated in the study. Cerebrospinal fluid samples were obtained by lumbar puncture and the concentrations of 12 species of lysophosphatidic acids and lysophosphatidylcholine, autotaxin, and the phosphorylated neurofilament heavy subunit were measured. Pain symptoms were assessed using an 11-point numeric rating scale and the Neuropathic Pain Symptom Inventory regarding intensity and descriptive dimensions of neuropathic pain. The total lysophosphatidic acids were significantly associated with both pain intensity and symptoms. 18:1 and 20:4 lysophosphatidic acids in particular demonstrated the most correlations with dimensions of pain symptoms. Autotaxin and the phosphorylated neurofilament heavy subunit showed no association with pain symptoms. In conclusions, lysophosphatidic acids were significantly associated with pain symptoms in neuropathic pain patients. These results suggest that lysophosphatidic acids signaling might be a potential therapeutic target for neuropathic pain.

Citing Articles

Clinical measures in chronic neuropathic pain are related to the Kennedy and endocannabinoid pathways.

Bourke S, Suarez E, Islam B, Stephenson J, Finn D, McHugh P Eur J Clin Invest. 2024; 55(2):e14351.

PMID: 39545479 PMC: 11744925. DOI: 10.1111/eci.14351.

Linking the Autotaxin-LPA Axis to Medicinal Cannabis and the Endocannabinoid System.

Eymery M, Boumendjel A, McCarthy A, Hausmann J Int J Mol Sci. 2024; 25(6).

PMID: 38542186 PMC: 10970320. DOI: 10.3390/ijms25063212.

Development of an advanced liquid chromatography-tandem mass spectrometry measurement system for simultaneous sphingolipid analysis.

Uranbileg B, Sakai E, Kubota M, Isago H, Sumitani M, Yatomi Y Sci Rep. 2024; 14(1):5699.

PMID: 38459112 PMC: 10923881. DOI: 10.1038/s41598-024-56321-w.

pharmacological characterization of standard and new lysophosphatidic acid receptor antagonists using dynamic mass redistribution assay.

Ruzza C, Argentieri M, Ferrari F, Armani E, Trevisani M, Marchini G Front Pharmacol. 2023; 14:1267414.

PMID: 38035009 PMC: 10682101. DOI: 10.3389/fphar.2023.1267414.

Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder.

Requena-Ocana N, Flores-Lopez M, Garcia-Marchena N, Pavon-Moron F, Pedraza C, Wallace A Int J Mol Sci. 2023; 24(21).

PMID: 37958570 PMC: 10649657. DOI: 10.3390/ijms242115586.

References

Matsubayashi Y, Takeshita K, Sumitani M, Oshima Y, Tonosu J, Kato S . Psychometric Validation of the Japanese Version of the Neuropathic Pain Symptom Inventory. PLoS One. 2015; 10(11):e0143350. PMC: 4658188. DOI: 10.1371/journal.pone.0143350. View

Rivera A, Vanzulli I, Butt A . A Central Role for ATP Signalling in Glial Interactions in the CNS. Curr Drug Targets. 2016; 17(16):1829-1833. DOI: 10.2174/1389450117666160711154529. View

Fujita R, Kiguchi N, Ueda H . LPA-mediated demyelination in ex vivo culture of dorsal root. Neurochem Int. 2006; 50(2):351-5. DOI: 10.1016/j.neuint.2006.09.003. View

Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E . Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004; 108(3):248-257. DOI: 10.1016/j.pain.2003.12.024. View

Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K . Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000; 478(1-2):159-65. DOI: 10.1016/s0014-5793(00)01827-5. View

Ueda H . Peripheral mechanisms of neuropathic pain - involvement of lysophosphatidic acid receptor-mediated demyelination. Mol Pain. 2008; 4:11. PMC: 2365930. DOI: 10.1186/1744-8069-4-11. View

Ma L, Nagai J, Chun J, Ueda H . An LPA species (18:1 LPA) plays key roles in the self-amplification of spinal LPA production in the peripheral neuropathic pain model. Mol Pain. 2013; 9:29. PMC: 3691926. DOI: 10.1186/1744-8069-9-29. View

Ueda H, Matsunaga H, Olaposi O, Nagai J . Lysophosphatidic acid: chemical signature of neuropathic pain. Biochim Biophys Acta. 2012; 1831(1):61-73. DOI: 10.1016/j.bbalip.2012.08.014. View

Inoue M, Ma L, Aoki J, Chun J, Ueda H . Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol Pain. 2008; 4:6. PMC: 2277392. DOI: 10.1186/1744-8069-4-6. View

10.

Forstenpointner J, Otto J, Baron R . Individualized neuropathic pain therapy based on phenotyping: are we there yet?. Pain. 2018; 159(3):569-575. DOI: 10.1097/j.pain.0000000000001088. View

11.

Tsuda M, Tozaki-Saitoh H, Inoue K . Purinergic system, microglia and neuropathic pain. Curr Opin Pharmacol. 2011; 12(1):74-9. DOI: 10.1016/j.coph.2011.10.014. View

12.

Nagai J, Uchida H, Matsushita Y, Yano R, Ueda M, Niwa M . Autotaxin and lysophosphatidic acid1 receptor-mediated demyelination of dorsal root fibers by sciatic nerve injury and intrathecal lysophosphatidylcholine. Mol Pain. 2010; 6:78. PMC: 2989310. DOI: 10.1186/1744-8069-6-78. View

13.

Boadas-Vaello P, Castany S, Homs J, Alvarez-Perez B, Deulofeu M, Verdu E . Neuroplasticity of ascending and descending pathways after somatosensory system injury: reviewing knowledge to identify neuropathic pain therapeutic targets. Spinal Cord. 2016; 54(5):330-40. DOI: 10.1038/sc.2015.225. View

14.

Wilkie D, Huang H, Reilly N, Cain K . Nociceptive and neuropathic pain in patients with lung cancer: a comparison of pain quality descriptors. J Pain Symptom Manage. 2001; 22(5):899-910. PMC: 3682837. DOI: 10.1016/s0885-3924(01)00351-7. View

15.

Ohya J, Chikuda H, Kato S, Hayakawa K, Oka H, Takeshita K . Elevated levels of phosphorylated neurofilament heavy subunit in the cerebrospinal fluid of patients with lumbar spinal stenosis: preliminary findings. Spine J. 2015; 15(7):1587-92. DOI: 10.1016/j.spinee.2015.03.013. View

16.

Hayakawa K, Okazaki R, Ishii K, Ueno T, Izawa N, Tanaka Y . Phosphorylated neurofilament subunit NF-H as a biomarker for evaluating the severity of spinal cord injury patients, a pilot study. Spinal Cord. 2012; 50(7):493-6. DOI: 10.1038/sc.2011.184. View

17.

Nakamura K, Igarashi K, Ide K, Ohkawa R, Okubo S, Yokota H . Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. Clin Chim Acta. 2007; 388(1-2):51-8. DOI: 10.1016/j.cca.2007.10.005. View

18.

Zhang Z, Jiang B, Gao Y . Chemokines in neuron-glial cell interaction and pathogenesis of neuropathic pain. Cell Mol Life Sci. 2017; 74(18):3275-3291. PMC: 11107618. DOI: 10.1007/s00018-017-2513-1. View

19.

Ueda H . Lysophosphatidic acid signaling is the definitive mechanism underlying neuropathic pain. Pain. 2017; 158 Suppl 1:S55-S65. DOI: 10.1097/j.pain.0000000000000813. View

20.

Nagai J, Ueda H . Pre-emptive morphine treatment abolishes nerve injury-induced lysophospholipid synthesis in mass spectrometrical analysis. J Neurochem. 2011; 118(2):256-65. DOI: 10.1111/j.1471-4159.2011.07297.x. View